XML 143 R63.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Significant Concentrations (Details)
$ in Thousands
12 Months Ended
Feb. 29, 2020
USD ($)
Mar. 02, 2019
USD ($)
derivative
Mar. 03, 2018
USD ($)
Mar. 15, 2019
USD ($)
Derivatives        
Number of interest rate swap arrangements or other derivatives held | derivative   0    
Interest rate cap        
Derivatives        
Derivative notional amount $ 650,000     $ 650,000
Interest rate cap (as a percent) 2.75%      
Interest rate cap | LIBOR        
Derivatives        
Interest rate cap (as a percent)       2.75%
Retail Pharmacy | Purchases | Suppliers | McKesson Corp.        
Significant Concentrations        
Percentage of concentration risk 99.00%      
Pharmacy sales | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Top five third party payors        
Significant Concentrations        
Percentage of concentration risk 79.90%      
Pharmacy sales | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Largest third party payor | Express Scripts        
Significant Concentrations        
Percentage of concentration risk     27.20%  
Pharmacy sales | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Largest third party payor | Caremark        
Significant Concentrations        
Percentage of concentration risk 28.80% 28.30%    
Pharmacy sales | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Medicaid agencies and related managed care Medicaid payors        
Significant Concentrations        
Percentage of concentration risk 19.00%      
Pharmacy sales | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Largest Medicaid agency        
Significant Concentrations        
Percentage of concentration risk 1.40%      
Pharmacy sales | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Medicare Part D        
Significant Concentrations        
Percentage of concentration risk 38.40%      
Pharmacy Services | Medicare Part D        
Significant Concentrations        
Net revenues $ 436,435 $ 391,024 $ 203,361  
Pharmacy Services | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Top Five Customers [Member]        
Significant Concentrations        
Percentage of concentration risk 53.20%      
Pharmacy Services | Revenue from Contract with Customer, Segment Benchmark [Member] | Customers | Largest Customer [Member]        
Significant Concentrations        
Percentage of concentration risk 27.40% 23.00% 17.30%  
Pharmacy Services | Consolidated revenues | Customers | Medicare Part D        
Significant Concentrations        
Percentage of concentration risk 2.00% 1.80% 1.00%